Evidence map›Paper›PMID 37790450›Full record

ArticleResearch square2023

Pooled endogenous protein tagging and recruitment for scalable discovery of effectors for induced proximity therapeutics.

Yevgeniy V Serebrenik, Deepak Mani, Timothé Maujean, George M Burslem, Ophir Shalem

Abstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yevgeniy V SerebrenikCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Deepak ManiCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Timothé MaujeanDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8268-608X
George M BurslemDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2812-983X
Ophir ShalemCenter for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Funding

Direct and rapid control of proteins at scaleDP2GM137416 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI SHALEM, OPHIR · 2019 to 2022
$2.8M
Editing Acetylation and Protein HomeostasisR35GM142505 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI George Burslem · 2021 to 2026
$2.7M
Dissecting the mechanisms that underlie mislocalization and aggregation of RNA binding proteins in neurodegenerative diseasesR03NS111447 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI SHALEM, OPHIR · 2019 to 2019
$352k
Uncovering cell factors with aggregate clearance activity by scalable induced proximityK99AG075256 · NIA · CHILDREN'S HOSP OF PHILADELPHIA · PI SEREBRENIK, YEVGENIY VLADIMIROVICH · 2022 to 2023
$259k
Rapid and direct control of the proteome through a multiplexed tag systemF32CA239499 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI SEREBRENIK, YEVGENIY VLADIMIROVICH · 2019 to 2021
$195k
NCI NIH HHS F32 CA239499NIA NIH HHS K99 AG075256NIGMS NIH HHS DP2 GM137416NIGMS NIH HHS R35 GM142505NINDS NIH HHS R03 NS111447
6 · The paper itself

Abstract

The field of induced proximity therapeutics is in its ascendancy but is limited by a lack of scalable tools to systematically explore effector-target protein pairs in an unbiased manner. Here, we combined Scalable POoled Targeting with a LIgandable Tag at Endogenous Sites (SPOTLITES) for the high-throughput tagging of endogenous proteins, with generic small molecule-based protein recruitment to screen for novel proximity-based effectors. We apply this methodology in two orthogonal screens for targeted protein degradation: the first using fluorescence to monitor target protein levels directly, and the second using a cellular growth phenotype that depends on the degradation of an essential protein. Our screens revealed a multitude of potential new effector proteins for degradation and converged on members of the CTLH complex which we demonstrate potently induce degradation. Altogether, we introduce a platform for pooled induction of endogenous protein-protein interactions that can be used to expand our toolset of effector proteins for targeted protein degradation and other forms of induced proximity.

Identifiers

PMID37790450
PMCPMC10543026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.